文献速递小儿麻醉心胸血管麻醉

环泊酚在儿科麻醉中的群体药代动力学-药效学分析与剂量优化

Population pharmacokinetic-pharmacodynamic analysis and dose optimisation of ciprofol in paediatric anaesthesia.
PubMed 文献 · Br J Anaesth · 2026-07-02

本研究纳入88例0.08-15岁、体重4.2-71.0 kg行心胸手术的儿科患者,以0.6或0.9 mg kg-1环泊酚诱导,建立popPK/PD模型。推荐诱导剂量0.6 mg kg-1,维持按体重分层输注1.0-1.4 mg kg-1 h-1,目标BIS 40-60。

要点

  • 推荐环泊酚儿科诱导剂量为0.6 mg kg-1。
  • 维持输注按体重分层:0-5 kg为1.4、5-30 kg为1.2、>30 kg为1.0 mg kg-1 h-1。
  • 仅在持续BIS监测下可升级至更高剂量以避免过度镇静。

核心结论

  • 推荐儿科麻醉采用环泊酚0.6 mg kg-1诱导,随后按体重分层维持输注1.0-1.4 mg kg-1 h-1。
  • 外推至3岁及以上儿童假设PD反应相似,需警惕该年龄组潜在不准确性。

研究设计与样本

  • 研究纳入88例0.08-15岁、体重4.2-71.0 kg行心脏或胸科手术的儿科患者。
  • 以0.6 mg kg-1或0.9 mg kg-1环泊酚诱导,采用机会性采血测定浓度并建立popPK/PD模型。
  • 在3岁以下儿童中采用效应室模型表征BIS与药物浓度的关系。

主要发现

  • 含体重与经验性成熟过程协变量的二室模型最优表征环泊酚PK。
  • 推荐诱导剂量为0.6 mg kg-1。
  • 基于模拟的体重分层输注方案目标BIS范围40-60。

关键数值与推荐

  • 维持输注推荐:体重0-5 kg为1.4 mg kg-1 h-1。
  • 维持输注推荐:体重5-30 kg为1.2 mg kg-1 h-1。
  • 维持输注推荐:体重>30 kg为1.0 mg kg-1 h-1。
  • 仅在持续BIS监测下可升级至更高剂量以避免过度镇静。

临床怎么用

  • 儿科麻醉可按0.6 mg kg-1环泊酚诱导。
  • 维持按体重分层输注1.0-1.4 mg kg-1 h-1并目标BIS 40-60。
  • 3岁及以上儿童外推用药需谨慎,注意PD反应潜在差异。

局限性

  • 外推至3岁及以上儿童假设PD反应相似,该年龄组可能存在不准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to explore the population pharmacokinetics and pharmacodynamics (popPK/PD) of ciprofol in paediatric patients and to provide references for dose optimisation of ciprofol as initiation and maintenance dosages in paediatric patients. METHODS: Anaesthesia was induced with ciprofol at doses of 0.6 mg kg-1 or 0.9 mg kg-1 in paediatric patients (n=88; 0.08-15 yr; weight, 4.2-71.0 kg) undergoing cardiac or thoracic surgery. Blood samples were collected using opportunistic blood sampling, and ciprofol concentration was determined by a validated analytical method. A popPK/PD model of ciprofol was developed. The relationship between bispectral index (BIS) and drug concentration was characterised by an effect compartment model in children younger than 3 yr of age. RESULTS: A two-compartment model with body weight and an empirical maturation process as covariates optimally characterised ciprofol PK. The recommended induction dose was 0.6 mg kg-1. Maintenance of anaesthesia which targeted an optimal BIS range of 40-60 using simulation-based, weight-stratified infusion regimens was recommended as follows: 1.4 mg kg-1 h-1 for patients weighing 0-5 kg, 1.2 mg kg-1 h-1 for those weighing 5-30 kg, and 1.0 mg kg-1 h-1 for patients weighing >30 kg, with escalation to higher doses only under continuous BIS monitoring to avoid oversedation. CONCLUSIONS: A ciprofol induction dose of 0.6 mg kg-1 followed by a weight-stratified maintenance infusion of 1.0-1.4 mg kg-1 h-1 is recommended for paediatric anaesthesia. Extrapolation to children 3 yr of age and older assumed similarity in PD response, and potential inaccuracy in this age group is cautioned. CLINICAL TRIAL REGISTRATION: ChiCTR2600118090.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Liu C, Wang Z, Zhou J, et al. Population pharmacokinetic-pharmacodynamic analysis and dose optimisation of ciprofol in paediatric anaesthesia. Br J Anaesth. 2026. PMID: 42392886. doi:10.1016/j.bja.2026.04.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。